コバヤシ ヒロヒト   Kobayashi Hirohito
  小林 博人
   所属   医学部 医学科(附属足立医療センター)
   職種   准教授
論文種別 原著
言語種別 英語
査読の有無 査読あり
表題 Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study.
掲載誌名 正式名:Cancer immunology, immunotherapy : CII
略  称:Cancer Immunol Immunother
ISSNコード:03407004/03407004
掲載区分国外
巻・号・頁 56(4),pp.469-76
著者・共著者 Kobayashi Hirohito, Tanaka Yoshimasa, Yagi Junji, Osaka Yukinari, Nakazawa Hayakazu, Uchiyama Takehiko, Minato Nagahiro, Toma Hiroshi
担当区分 筆頭著者
発行年月 2007/04
概要 PURPOSE:Although various types of immunotherapy have been used to improve the prognosis of patients with advanced renal cell carcinoma (RCC), adoptive immunotherapy using gamma-delta (gammadelta) T cells has not yet been tried. In this study, we designed a pilot study of adoptive immunotherapy using in vitro activated gammadelta T cells against advanced RCC to evaluate the safety profile and possible anti-tumor effects of this study.EXPERIMENTAL DESIGN:Patients with advanced RCC after radical nephrectomy were administered via intravenous infusion in vitro-activated autologous gammadelta T cells every week or every 2 weeks, 6-12 times, with 70 JRU of teceleukin. Adverse events, anti-tumor effects and immunomonitoring were assessed. The anti-tumor effects were evaluated according to tumor doubling time (DT) by computed tomography (CT) and immunomonitoring was performed by flow cytometric analysis.RESULTS:Seven advanced RCC patients were entered in this study. The most common adverse events were fever, general fatigue and elevation of hepatobiliary enzymes, but no severe adverse events were seen. Prolongation of tumor DT was seen in three out of five patients; these three patients showed an increase in the number of gammadelta T cells in peripheral blood and also a high response to the antigen in vitro.CONCLUSIONS:The results indicated that adoptive immunotherapy using in vitro-activated autologous gammadelta T cells was well tolerated and induced anti-tumor effects.
DOI 10.1007/s00262-006-0199-6
PMID 16850345